XML 91 R74.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Data (Unaudited ) (Summary of Quarterly Results of Operations) (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Quarterly Financial Data [Line Items]                      
Total revenues $ 699 $ 538 $ 630 [1] $ 1,659 [2] $ 3,715 [3] $ 360 $ 414 $ 476 $ 3,526 [1],[2] $ 4,965 [3] $ 23,053
Loss from operations (2,310) (2,727) (17,643) [1] (2,531) [2] (308) [3] (3,139) (3,121) (3,435) (25,211) [1],[2] (10,003) [3] 9,091
Net loss $ (2,262) $ (2,686) $ (17,460) [1] $ (2,427) [2] $ (140) [3] $ (2,685) $ (2,695) $ (3,108) $ (24,835) [1],[2] $ (8,628) [3] $ 8,753
Basic and diluted $ (0.11) $ (0.13) $ (0.84) [1] $ (0.12) [2] $ (0.01) [3] $ (0.13) $ (0.15) $ (0.17) $ (1.19) [1],[2] $ (0.44) [3]  
Basic and diluted 20,803 20,803 20,803 [1] 20,757 [2] 20,745 [3] 20,177 18,531 18,531 20,791 [1],[2] 19,489 [3]  
[1] Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).
[2] Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)
[3] Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).